|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for United States Patent 8,263,120
What does U.S. Patent 8,263,120 cover?
U.S. Patent 8,263,120, issued on September 11, 2012, to Novartis AG, claims a specific method of treating certain types of cancer using a combination therapy comprising an HSP90 inhibitor and a chemotherapeutic agent. The patent's primary focus is on the treatment of HER2-positive breast cancer and other HER2-expressing malignancies.
Scope of the Patent
The patent's scope encompasses pharmaceutical compositions and methods for treating HER2-positive tumors via combination therapy. The core claims include:
- Use of an HSP90 inhibitor, such as 17-AAG (tanespimycin), in conjunction with chemotherapeutic agents like trastuzumab or paclitaxel.
- Methods involving administering an effective amount of the combination to treat HER2-positive cancers.
- The compositions comprising specific combinations of HSP90 inhibitors with certain chemotherapeutic agents.
Key Claims Breakdown
| Claim Type |
Description |
Limitation/Scope |
| Independent Claims |
Claim 1 and 16 are core claims covering the use of a combination of an HSP90 inhibitor with a chemotherapeutic agent for treating HER2-positive cancers |
Focus on HER2-positive breast cancers, including specific HSP90 inhibitors (e.g., 17-AAG, IPI-504) and specific chemotherapeutic agents (e.g., trastuzumab, paclitaxel) |
| Dependent Claims |
Claims that specify particular dosages, formulations, administration routes, or combinations |
Narrowed scope targeting specific embodiments, e.g., doses, treatment regimens, or drug formulations |
Claim Language Precision
- Claim 1 states: "A method of treating HER2-positive breast cancer comprising administering an effective amount of an HSP90 inhibitor and a chemotherapeutic agent."
- Claim 16 extends similar claims to other HER2-expressing cancers, broadening the scope to include additional tumor types.
Patent Landscape and Related Patents
Priority and Family Members
The patent family includes applications filed in multiple jurisdictions, including:
- Europe (EP 2,415,418)
- Japan (JP 2014-514772)
- Canada (CA 2804237)
This family expands the rights into major markets for oncology drugs.
Competitor Patent Activities
- Several patents relate to HSP90 inhibitors, including tyrosine kinase inhibitors, with filings from Merck, Array BioPharma, and other biotech entities.
- Patents citing or citing this patent focus on HSP90 inhibitors' compositions, formulations, or specific combinations with other therapies.
Patent Term and Expiry
- U.S. Patent 8,263,120 has a filing date in September 2010 and a priority date of November 2008.
- The patent expires in September 2028, subject to patent term adjustments, potentially affecting the timing of generic entry.
Circling Back to Compatibility and Patentability
- The patent's claims are consistent with the known mode of action of HSP90 inhibitors: destabilizing client proteins essential for tumor survival.
- The combination therapy claims face challenges in non-obviousness if prior art discloses similar combinations, although the specific drugs and methods claimed provide some novelty.
What are potential challenges or patenting strategies?
- Challenge: Prior art exists for individual use of HSP90 inhibitors and for combinations with chemotherapeutics, raising questions of inventive step.
- Strategy: Focus on specific drug combinations, doses, or treatment regimens not previously disclosed.
Summary of Patent Office and Litigation Status
- The patent is maintained through standard fee payments.
- No public information indicates ongoing litigation.
- Commercialization hinges on this patent protecting combination therapy for HER2+ breast cancer from generic competitors until 2028.
Key Takeaways
- U.S. Patent 8,263,120 covers specific methods and compositions for treating HER2-positive cancers using HSP90 inhibitors alongside chemotherapeutic agents.
- Claims are primarily method-based with particular emphasis on combination therapy.
- The patent landscape includes family members across key markets, with expiry in 2028.
- Competitors have active patent filings related to HSP90 inhibitor compositions and uses, requiring careful freedom-to-operate analysis.
- Innovating around specific drug combinations or treatment protocols remains essential as prior art advances.
FAQs
1. What is the primary therapeutic focus of U.S. Patent 8,263,120?
Treatment of HER2-positive breast cancers using HSP90 inhibitors combined with chemotherapeutic agents.
2. Which drugs are specifically mentioned in the patent claims?
17-AAG (tanespimycin), trastuzumab, paclitaxel, among others.
3. When does the patent expire?
In September 2028, subject to patent term adjustments.
4. Are there related patents in other jurisdictions?
Yes, family members exist in Europe, Japan, and Canada.
5. What are common patentability challenges for this patent?
Prior art on individual and combination uses of HSP90 inhibitors, requiring differentiation through specific drug regimens or compositions.
References
[1] U.S. Patent 8,263,120. (2012). Methods of treating HER2-positive cancers using HSP90 inhibitors.
[2] European Patent EP 2415418. (2013). Combination therapies involving HSP90 inhibitors.
[3] Japan Patent JP 2014-514772. (2014). HSP90 inhibitor formulations and combinations.
More… ↓
⤷ Start Trial
|
